Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry

被引：15

作者：

Jagannath, Sundar ^{[1
]}

Rifkin, Robert M. ^{[2
]}

Gasparetto, Cristina J. ^{[3
]}

Toomey, Kathleen ^{[4
]}

Durie, Brian G. M. ^{[5
]}

Hardin, James W. ^{[6
]}

Terebelo, Howard R. ^{[7
]}

Wagner, Lynne ^{[8
]}

Narang, Mohit ^{[9
]}

Ailawadhi, Sikander ^{[10
]}

Omel, James L.

Srinivasan, Shankar ^{[11
]}

He, Mia ^{[11
]}

Ung, Brian ^{[11
]}

Kitali, Amani ^{[11
]}

Flick, E. Dawn ^{[11
]}

Agarwal, Amit ^{[11
]}

Abonour, Rafat ^{[12
]}

机构：

[1] Mt Sinai Hosp, Dept Hematol & Med Oncol, New York, NY 10029 USA

[2] Rocky Mt Canc Ctr US Oncol, Dept Med Oncol Hematol, Denver, CO USA

[3] Duke Univ, Med Ctr, Dept Hematol Malignancies & Cellular Therapy, Durham, NC USA

[4] Steeplechase Canc Ctr, Dept Internal Med Med Oncol & Hematol, Somerville, NJ USA

[5] Cedars Sinai Med Ctr, Dept Hematol Oncol, Los Angeles, CA 90048 USA

[6] Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA

[7] Providence Canc Inst, Dept Hematol Internal Med & Med Oncol, Southfield, MI USA

[8] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27101 USA

[9] US Oncol Res, Dept Med Hematol Oncol, Columbia, MD USA

[10] Mayo Clin, Dept Hematol, Jacksonville, FL 32224 USA

[11] Celgene Corp, Summit, NJ USA

[12] Indiana Univ, Dept Hematol Oncol, Indianapolis, IN 46204 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 05期

关键词：

Community; Real-world; Sankey; Therapies; Transitions;

D O I：

10.1016/j.clml.2019.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：272 / 276

页数：5

共 50 条

[41] Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
Nandakumar, Bharat
Kapoor, Prashant
Binder, Moritz
Buadi, Francis K.
Lacy, Martha Q.
Gertz, Morie A.
Dispenzieri, Angela
Dingli, David
Hwa, Yi L.
Fonder, Amie
Hobbs, Miriam A.
Hayman, Suzanne R.
Lust, John A.
Russell, Stephen J.
Leung, Nelson
Go, Ronald S.
Lin, Yi
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Warsame, Rahma M.
Siddiqui, Mustaqeem A.
Kyle, Robert A.
Rajkumar, S. Vincent
Kumar, Shaji K.
BLOOD, 2020, 136
[42] Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.
Jagannath, Sundar
Abonour, Rafat
Durie, Brian G.
Shah, Jatin J.
Narang, Mohit
Terebelo, Howard R.
Gasparetto, Cristina
Toomey, Kathleen
Hardin, James W.
Wagner, Lynne I.
Agarwal, Amit
Srinivasan, Shankar
Kitali, Amani
Zafar, Faiza
Sturniolo, Michael
Rifkin, Robert M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] From guidelines to real world: results from the National Multiple Myeloma Registry in Uruguay on 222 newly diagnosed multiple myeloma patients from 2012 to 2015
Riva, E.
Bove, V
Villano, F.
Mori, M.
Cordoba, C.
Noria, A.
Petruskevicius, P.
Cardeza, A.
Diaz, L.
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1197 - 1203
[44] Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM)
Martin, Thomas G., III
Panjabi, Sumeet
Kerr, Jiandong
Martin, Michael G.
Walker, Mark S.
BLOOD, 2013, 122 (21)
[45] Myeloma XI Trial - Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients
Jones, John
Pawlyn, Charlotte
Brioli, Annamaria
Cairns, David A.
Quartillo, Ana
Sigsworth, Rachel
Howard, Helen
Collett, Corinne
Ouzman, Jacqueline
Gregory, Walter
Russell, Nigel
Jacksons, Graham H.
Davies, Faith E.
Morgan, Gareth J.
BLOOD, 2014, 124 (21)
[46] Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
White, Darrell
Lipe, Brea
Gironella Mesa, Mercedes
Niesvizky, Ruben
Oriol, Albert
Sureda Balari, Anna
Bhutani, Manisha
Encinas, Cristina
Khan, Abdullah
Amatangelo, Michael
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
van de Donk, Niels
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S25 - S25
[47] TREATMENT SATISFACTION AND BURDEN OF ILLNESS WITH ORAL VS INJECTABLE MULTIPLE MYELOMA THERAPY IN PATIENTS WITH NEWLY DIAGNOSED DISEASE (NDMM)
Romanus, D.
DasMahapatra, P.
Hoole, M.
Lowe, M.
Lawler, E.
Curran, C.
Campbell, S.
Bell, J.
VALUE IN HEALTH, 2017, 20 (09) : A454 - A454
[48] Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry
Abonour, Rafat
Durie, Brian
Jagannath, Sundar
Shah, Jatin
Narang, Mohit
Terebelo, Howard
Gasparetto, Cristina
Toomey, Kathleen
Hardin, James
Kitali, Amani
Gibson, Craig J.
Srinivasan, Shankar
Swern, Arlene
Rifkin, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E89 - E90
[49] Treatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, Maria-Victoria
Ocio, Enrique M.
Paiva, Bruno
Rosinol, Laura
Martinez-Lopez, Joaquin
Blade, Joan
Lahuerta, Juan-Jose
Garcia-Sanz, Ramon
San Miguel, Jesus F.
BLOOD REVIEWS, 2015, 29 (06) : 387 - 403
[50] A COST-BENEFIT ASSESSMENT OF TREATMENT (TX) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: AN EFFICIENCY FRONTIER APPROACH
Guo, S.
Pelligra, C.
Icten, Z.
Altincatal, A.
Rodrigues, F.
Monzini, M.
Knopf, K.
HAEMATOLOGICA, 2013, 98 : 214 - 214

← 1 2 3 4 5 →